clinical trials

A landmark study is due to start in the coming months, and if successful it could ultimately revive our immune system in older age and even treat chronic illnesses like autoimmune disease. The Phase 1 trial is aiming to rejuvenate senescent T cells.

Definium Therapeutics has announced the strong Phase 3 results of its single-dosed lysergide drug DT120 in treating adults with major depressive disorder. It met its main goal and all key secondary efficacy endpoints in the first trial of its kind.

We may be on the cusp of understanding whether we can turn back time for our cells to stave off age-related disease, with the first human receiving experimental gene therapy as part of a landmark trial.

We might be on the verge of a critical breakthrough treatment for pattern hair loss, with a novel slow-release oral drug meeting its significant endpoints in a Phase II/III trial of 519 patients. The next results are due later this year.

In a breakthrough study, researchers have found that the world's most common type of arthritis – osteoarthritis (OA) – actually has a single core driver with clean-cut molecular pathways. It paves the way for much better treatment.

Scientists are confident they've got the first effective Lyme disease vaccine, but the final hurdle will be FDA approval – which the drug-makers are seeking despite unexpected statistical issues. It remains to be seen if this will derail their goals.

The Food and Drug Administration has approved a landmark eye drop that uses a combined dose of medication to restore age-related near-sightedness, without the need for surgery, for longer than anything else on the market – and with fewer side effects.

A new CRISPR-based one-off therapy that lowers "bad" cholesterol is set to enter its Phase I trial. If successful, it could be the first approved genetic-editing method, replacing ongoing medication and slashing the risk of cardiovascular disease.

The first-of-a-kind brain-stimulation device approved to treat attention-deficit/hyperactivity disorder in the US has had its efficacy questioned, with scientists believing that its Food and Drug Administration approval was based on poor science.

In a landmark shift in how mental health conditions are treated in the near future, the US Food and Drug Administration has approved the first at-home brain-stimulation device that can rapidly relieve moderate to severe depression symptoms.

Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration approving a novel oral pill that helps prevent motion-induced vomiting – the first of its kind in more than 40 years.

The next transformative phase of weight-loss medication is upon us, with the US Food and Drug Administration (FDA) approving Novo Nordisk's highly anticipated oral GLP-1 drug – with a starting dose available in early January for US$149.